Fig. 4From: Evaluation of a novel ovarian cancer-specific fluorescent antibody probe for targeted near-infrared fluorescence imagingNIRF imaging and bioluminescent imaging (BLI) of different mouse groups at 6, 24, 48, 72 and 96 h postinjectionBack to article page